
  
    
      
        Background_NNP
        Coronary_NNP heart_NN disease_NN is_VBZ the_DT leading_VBG cause_NN of_IN death_NN in_IN
        the_DT United_NNP States_NNPS ._. [_NN 1_CD ]_NN Each_DT year_NN ,_, more_JJR than_IN 1_CD ,_, 000_CD ,_, 000_CD
        Americans_NNPS experience_NN new_JJ or_CC recurrent_JJ myocardial_NN infarction_NN
        or_CC fatal_JJ coronary_JJ heart_NN disease_NN (_( CHD_NNP )_) ._. About_IN one-third_NN of_IN
        these_DT events_NNS will_MD be_VB fatal_JJ ,_, and_CC approximately_RB 650_CD ,_, 000_CD of_IN
        these_DT events_NNS will_MD be_VB a_DT first_JJ myocardial_NN infarction_NN ._. The_DT
        direct_JJ and_CC indirect_JJ costs_NNS of_IN CHD_NNP and_CC stroke_NN are_VBP estimated_VBN
        to_TO be_VB $_$ 130_CD billion_CD for_IN 2003_CD ._. [_NN 2_CD ]_NN Fortunately_RB ,_, there_EX are_VBP a_DT
        number_NN of_IN interventions_NNS that_WDT can_MD reduce_VB the_DT risk_NN of_IN CHD_NNP
        events_NNS in_IN patients_NNS with_IN no_DT previous_JJ history_NN of_IN CHD_NNP ,_,
        including_VBG smoking_NN cessation_NN counseling_NN ,_, hypertension_NN
        treatment_NN ,_, aspirin_NN prophylaxis_NNS ,_, and_CC treatment_NN of_IN lipid_NN
        disorders_NNS ._. [_NN 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN
        Systematic_NNP reviews_NNS and_CC recent_JJ trials_NNS have_VBP found_VBN that_IN
        lipid-lowering_JJ therapy_NN with_IN HMG_NNP co-_NN A_DT reductase_NN inhibitors_NNS
        (_( statins_NNS )_) can_MD reduce_VB the_DT relative_JJ risk_NN of_IN future_JJ CHD_NNP events_NNS
        by_IN approximately_RB 30_CD %_NN and_CC that_IN this_DT relative_JJ risk_NN reduction_NN
        appears_VBZ to_TO be_VB similar_JJ for_IN patients_NNS with_IN different_JJ levels_NNS of_IN
        CHD_NNP risk_NN ._. [_NN 7_CD ]_NN ._. These_DT findings_NNS suggest_VBP that_IN the_DT absolute_JJ
        benefit_NN from_IN statin_NN therapy_NN is_VBZ proportional_JJ to_TO the_DT
        patient_NN 's_POS baseline_NN level_NN of_IN CHD_NNP risk_NN ._. Patients_NNS with_IN a_DT
        previous_JJ history_NN of_IN cardiovascular_JJ disease_NN (_( CVD_NNP )_) are_VBP at_IN
        high_JJ risk_NN and_CC generally_RB warrant_VB aggressive_JJ treatment_NN ;_:
        patients_NNS with_IN no_DT previous_JJ CVD_NNP history_NN have_VBP a_DT wide_JJ range_NN of_IN
        underlying_VBG CHD_NNP risk_NN and_CC hence_RB require_VB individualized_JJ
        decisions_NNS for_IN optimal_NN care_NN ._. In_IN order_NN to_TO make_VB effective_JJ and_CC
        efficient_JJ decisions_NNS about_IN whether_IN a_DT patient_NN without_IN prior_JJ
        CVD_NNP should_MD receive_VB lipid-lowering_JJ drugs_NNS ,_, providers_NNS must_MD
        implicitly_RB or_CC explicitly_RB consider_VB the_DT patient_NN 's_POS risk_NN of_IN
        future_JJ CHD_NNP events_NNS ._.
        Previous_JJ research_NN examining_VBG providers_NNS '_POS ability_NN to_TO
        estimate_VB cardiovascular_JJ risk_NN has_VBZ shown_VBN that_IN providers_NNS
        generally_RB overestimate_NN the_DT absolute_JJ risk_NN of_IN CHD_NNP events_NNS but_CC
        are_VBP more_RBR accurate_JJ in_IN their_PRP$ assessment_NN of_IN relative_JJ risk_NN
        reductions_NNS ._. [_NN 8_CD 9_CD 10_CD 11_CD 12_CD ]_NN If_IN providers_NNS overestimate_NN the_DT
        absolute_JJ risk_NN of_IN CHD_NNP events_NNS prior_RB to_TO treatment_NN ,_, their_PRP$
        estimates_NNS of_IN the_DT absolute_JJ benefit_NN of_IN therapy_NN may_MD also_RB be_VB
        inaccurate_JJ ._. Previous_JJ studies_NNS examining_VBG this_DT question_NN have_VBP
        only_RB studied_VBN risk_NN prediction_NN for_IN a_DT limited_JJ number_NN of_IN
        patient_NN care_NN scenarios_NNS ,_, making_VBG it_PRP difficult_JJ to_TO examine_VB how_WRB
        specific_JJ patient_NN characteristics_NNS or_CC the_DT degree_NN of_IN baseline_NN
        risk_NN (_( low_JJ ,_, medium_NN ,_, or_CC high_JJ risk_NN )_) affect_VB risk_NN prediction_NN and_CC
        the_DT amount_NN or_CC degree_NN of_IN overestimation_NN ._.
        We_PRP sought_VBD to_TO examine_VB physicians_NNS '_POS ability_NN to_TO predict_VB the_DT
        risk_NN of_IN CHD_NNP events_NNS and_CC the_DT effect_NN of_IN pharmacological_JJ
        lipid-lowering_JJ therapy_NN for_IN a_DT wide_JJ range_NN of_IN primary_JJ
        prevention_NN scenarios_NNS by_IN asking_VBG physicians_NNS at_IN three_CD academic_JJ
        medical_JJ centers_NNS to_TO complete_VB a_DT survey_NN of_IN 12_CD hypothetical_JJ
        scenarios_NNS concerning_VBG patients_NNS with_IN different_JJ levels_NNS of_IN CHD_NNP
        risk_NN ._.
      
      
        Methods_NNP
        
          Questionnaire_NNP Development_NNP
          We_PRP used_VBD the_DT Framingham_NNP risk_NN equations_NNS [_NN 13_CD ]_NN to_TO
          develop_VB 12_CD primary_JJ prevention_NN scenarios_NNS with_IN 5_CD -_: year_NN risk_NN
          of_IN CHD_NNP events_NNS (_( defined_VBN as_IN new_JJ onset_NN angina_NN ,_, non-fatal_JJ or_CC
          fatal_JJ MI_NNP ,_, or_CC sudden_JJ death_NN )_) from_IN 1_CD to_TO 22_CD per_IN cent_NN ._. The_DT
          scenarios_NNS were_VBD balanced_VBN with_IN regard_NN to_TO gender_VB (_( 6_CD male_JJ
          patients_NNS ,_, 6_CD female_JJ patients_NNS )_) and_CC included_VBD 4_CD low-risk_JJ
          scenarios_NNS (_( less_JJR than_IN 5_CD %_NN risk_NN of_IN CHD_NNP events_NNS over_IN 5_CD years_NNS )_) ,_,
          4_CD medium_NN risk_NN scenarios_NNS (_( 5_CD -_: year_NN risk_NN of_IN 5_CD -_: 9_CD %_NN )_) ,_, and_CC 4_CD
          high-risk_JJ scenarios_NNS (_( 5_CD -_: year_NN risk_NN 10_CD -_: 22_CD %_NN )_) ._. Six_CD of_IN the_DT
          scenarios_NNS had_VBD one_CD or_CC no_DT additional_JJ risk_NN factors_NNS (_( not_RB
          including_VBG age_NN ,_, gender_NN ,_, or_CC lipid_NN levels_NNS )_) ,_, while_IN the_DT other_JJ
          6_CD scenarios_NNS had_VBD 2_CD or_CC more_RBR additional_JJ risk_NN factors_NNS ._.
          The_DT hypothetical_JJ patients_NNS were_VBD explicitly_RB assumed_VBN :_: 1_LS )_)
          to_TO not_RB be_VB taking_VBG aspirin_NN or_CC lipid-lowering_JJ agents_NNS at_IN
          baseline_NN ;_: 2_LS )_) to_TO not_RB have_VB responded_VBN to_TO a_DT trial_NN of_IN a_DT
          low-fat_JJ diet_NN ;_: 3_LS )_) ,_, to_TO not_RB be_VB overweight_NN ;_: and_CC 4_LS )_) to_TO not_RB
          have_VB a_DT family_NN history_NN of_IN early_JJ myocardial_NN infarction_NN ._. We_PRP
          did_VBD not_RB specify_VB the_DT patient_NN 's_POS ethnicity_NN ,_, as_IN we_PRP did_VBD not_RB
          wish_VB to_TO examine_VB its_PRP$ effect_NN in_IN this_DT study_NN ._.
          The_DT questionnaire_NN was_VBD pilot_NN tested_VBN in_IN two_CD different_JJ
          groups_NNS of_IN primary_JJ care_NN providers_NNS and_CC preventive_JJ medicine_NN
          residents_NNS at_IN one_CD of_IN the_DT study_NN sites_NNS and_CC was_VBD revised_VBN based_VBN
          on_IN their_PRP$ feedback_NN ._.
        
        
          Study_NNP Subjects_NNP and_CC Administration_NNP
          In_IN the_DT fall_NN of_IN 1998_CD we_PRP administered_VBN the_DT survey_NN to_TO
          residents_NNS ,_, fellows_NNS ,_, and_CC attending_VBG physicians_NNS at_IN three_CD
          university_NN sites_NNS ._. Potential_JJ respondents_NNS were_VBD invited_VBN to_TO a_DT
          lunch_NN meeting_NN in_IN which_WDT they_PRP would_MD complete_VB a_DT survey_NN on_IN
          preventive_JJ care_NN ._. They_PRP provided_VBD informed_VBN consent_NN and_CC then_RB
          completed_VBD the_DT survey_NN over_IN the_DT course_NN of_IN the_DT next_JJ 20_CD -_: 30_CD
          minutes_NNS ._. Subjects_NNP were_VBD not_RB allowed_VBN to_TO use_VB decision_NN aids_NNS
          or_CC other_JJ external_JJ information_NN ._. The_DT protocol_NN was_VBD
          considered_VBN exempt_JJ by_IN the_DT UNC_NNP Institutional_NNP Review_NNP
          Board_NNP ._.
        
        
          Outcome_NNP Measures_NNS
          For_IN each_DT scenario_NN ,_, we_PRP first_RB asked_VBD subjects_NNS to_TO estimate_VB
          the_DT 5_CD -_: year_NN risk_NN of_IN CHD_NNP events_NNS without_IN any_DT therapy_NN ,_, then_RB
          to_TO estimate_VB the_DT 5_CD -_: year_NN risk_NN if_IN the_DT patient_NN were_VBD taking_VBG a_DT
          lipid-lowering_JJ agent_NN ._. We_PRP used_VBD a_DT 5_CD -_: year_NN time_NN range_NN ,_, rather_RB
          than_IN the_DT 10_CD -_: year_NN range_NN used_VBN by_IN some_DT risk_NN estimation_NN
          tools_NNS ,_, because_IN trials_NNS examining_VBG the_DT benefits_NNS of_IN
          lipid-lowering_JJ therapy_NN were_VBD performed_VBN over_IN a_DT mean_NN of_IN 5_CD
          years_NNS ,_, making_VBG estimates_NNS of_IN treatment_NN effectiveness_NN over_IN
          this_DT time_NN period_NN most_RBS robust_JJ ._. Finally_RB ,_, providers_NNS were_VBD
          asked_VBN to_TO indicate_VB on_IN a_DT 4_CD -_: point_NN Likert_NNP scale_NN if_IN they_PRP would_MD
          recommend_VB that_IN the_DT patient_NN take_NN lipid-lowering_JJ therapy_NN ,_,
          with_IN responses_NNS ranging_VBG from_IN "_'' strongly_RB recommend_VB therapy_NN "_''
          to_TO "_'' strongly_RB recommend_VB against_IN therapy_NN "_'' ._. For_IN these_DT
          analyses_NNS ,_, strong_JJ or_CC moderate_JJ recommendations_NNS for_IN therapy_NN
          were_VBD considered_VBN as_IN positive_NN ._.
        
        
          Analysis_NNP
          Data_NNS from_IN completed_VBN surveys_NNS were_VBD entered_VBN and_CC analyzed_VBD
          using_VBG STATA_NNP 6_CD ._. 0_CD ._. (_( Stata_NNP Corporation_NNP ,_, College_NNP Station_NNP ,_, Tx_NNP )_)
          and_CC Microsoft_NNP Excel_NNP (_( Microsoft_NNP ,_, Redmond_NNP ,_, WA_NNP )_) ._. Univariate_NNP
          frequencies_NNS are_VBP presented_VBN as_IN proportions_NNS ,_, means_VBZ ,_, and_CC
          medians_NNS ._. We_PRP measured_VBD the_DT accuracy_NN of_IN CHD_NNP risk_NN prediction_NN
          by_IN dividing_VBG the_DT subjects_NNS '_POS estimate_NN of_IN risk_NN by_IN the_DT risk_NN
          obtained_VBN from_IN the_DT Framingham_NNP model_NN and_CC considering_VBG
          results_NNS from_IN 0_CD ._. 67_CD to_TO 1_CD ._. 5_CD to_TO be_VB accurate_JJ ._. The_DT accuracy_NN of_IN
          physicians_NNS '_POS estimates_NNS of_IN CHD_NNP risk_NN after_IN therapy_NN with_IN
          lipid-lowering_JJ drugs_NNS was_VBD examined_VBN by_IN calculating_VBG the_DT
          relative_JJ risk_NN reduction_NN (_( RRR_NNP ,_, defined_VBN as_IN the_DT baseline_NN
          risk_NN -_: risk_NN after_IN therapy_NN ,_, divided_VBN by_IN the_DT baseline_NN risk_NN )_)
          and_CC comparing_VBG it_PRP against_IN a_DT value_NN of_IN 30_CD %_NN derived_VBN from_IN a_DT
          meta-analysis_JJ of_IN primary_JJ prevention_NN trials_NNS ._. [_NN 7_CD ]_NN
          Relative_NNP risk_NN reductions_NNS between_IN 25_CD and_CC 40_CD %_NN were_VBD
          considered_VBN to_TO be_VB accurate_JJ ._. To_TO examine_VB patient_NN factors_NNS
          that_WDT may_MD be_VB associated_VBN with_IN the_DT accuracy_NN of_IN risk_NN
          estimation_NN ,_, we_PRP compared_VBD the_DT mean_JJ relative_JJ
          over-estimations_JJ for_IN scenarios_NNS using_VBG patients_NNS with_IN the_DT
          factor_NN compared_VBN with_IN scenarios_NNS of_IN patients_NNS without_IN the_DT
          factor_NN ,_, using_VBG Wilcoxon_NNP rank_NN sum_NN tests_NNS for_IN univariate_NN
          analyses_NNS and_CC linear_JJ regression_NN for_IN multivariate_NN
          analysis_NN ._.
          We_PRP did_VBD not_RB attempt_VB to_TO compare_VB the_DT risk_NN prediction_NN
          ability_NN of_IN residents_NNS (_( compared_VBN with_IN attendings_NNS )_) or_CC
          cardiologists_NNS (_( compared_VBN with_IN generalists_NNS )_) because_IN of_IN the_DT
          small_JJ numbers_NNS of_IN participants_NNS in_IN each_DT sub-group_JJ ._.
        
      
      
        Results_NNS
        
          Accuracy_NNP of_IN risk_NN estimates_NNS
          Across_IN all_DT 12_CD scenarios_NNS ,_, risk_NN estimates_NNS were_VBD accurate_JJ
          (_( a_DT response_NN between_IN 0_CD ._. 67_CD and_CC 1_CD ._. 5_CD times_NNS the_DT actual_JJ value_NN )_)
          for_IN only_RB 24_CD %_NN of_IN the_DT responses_NNS ._. Most_JJS physicians_NNS
          overestimated_JJ the_DT 5_CD -_: year_NN risk_NN of_IN CHD_NNP :_: for_IN all_DT scenarios_NNS
          combined_VBN ,_, 66_CD %_NN of_IN responses_NNS were_VBD overestimates_NNS ,_, defined_VBN as_IN
          1_CD ._. 5_CD times_NNS greater_JJR than_IN the_DT actual_JJ value_NN ._. For_IN the_DT 12_CD
          individual_JJ questions_NNS ,_, the_DT proportion_NN of_IN physicians_NNS
          overestimating_VBG risk_NN ranged_VBD from_IN 33_CD to_TO 99_CD %_NN ._. Fewer_JJR
          providers_NNS underestimated_VBD risk_NN :_: 10_CD %_NN responses_NNS were_VBD
          underestimates_NNS (_( less_JJR than_IN 0_CD ._. 67_CD times_NNS the_DT actual_JJ value_NN )_) ._.
          For_IN the_DT 12_CD individual_JJ scenarios_NNS ,_, the_DT proportion_NN of_IN
          physicians_NNS underestimating_VBG risk_NN ranged_VBD from_IN 0_CD to_TO 29_CD %_NN ._.
          When_WRB an_DT alternative_JJ definition_NN of_IN accuracy_NN (_( estimates_NNS
          within_IN 10_CD percentage_NN points_NNS of_IN the_DT true_JJ value_NN )_) ,_, similar_JJ
          patterns_NNS were_VBD noted_VBN ._.
        
        
          Estimation_NNP of_IN relative_JJ risk_NN reduction_NN
          Physicians_NNPS were_VBD more_RBR accurate_JJ in_IN their_PRP$ ability_NN to_TO
          estimate_VB the_DT relative_JJ risk_NN reduction_NN that_WDT would_MD be_VB
          associated_VBN with_IN lipid-lowering_JJ therapy_NN :_: 43_CD %_NN of_IN estimates_NNS
          were_VBD accurate_JJ ._. By_IN scenario_NN ,_, the_DT range_NN of_IN accurate_JJ
          calculated_VBN RRR_NNP was_VBD 29_CD to_TO 53_CD %_NN ._.
        
        
          Treatment_NNP recommendations_NNS
          Most_JJS physicians_NNS (_( over_IN 85_CD %_NN in_IN scenarios_NNS #_# 3_CD -_: 12_CD ;_: 32_CD %_NN in_IN
          scenario_NN #_# 1_CD and_CC 67_CD %_NN in_IN scenario_NN #_# 2_LS )_) recommended_VBD treatment_NN
          with_IN statin_NN drugs_NNS ._. The_DT two_CD scenarios_NNS with_IN lower_JJR treatment_NN
          recommendation_NN rates_NNS were_VBD the_DT two_CD of_IN the_DT four_CD lowest_JJS risk_NN
          scenarios_NNS ._.
        
        
          Patient_NNP factors_NNS affecting_VBG degree_NN of_IN risk_NN
          over-estimation_JJ
          The_DT mean_JJ degree_NN of_IN over-estimation_JJ ,_, expressed_VBD in_IN
          relative_JJ terms_NNS ,_, was_VBD larger_JJR for_IN low-risk_JJ scenarios_NNS (_( mean_VB
          physician_NN estimate_NN 7_CD ._. 8_CD times_NNS Framingham_NNP estimate_NN )_) ,_,
          intermediate_JJ for_IN medium_NN risk_NN scenarios_NNS (_( 2_CD ._. 8_CD times_NNS )_) ,_, and_CC
          smaller_JJR (_( 1_CD ._. 5_LS times_NNS )_) for_IN high-risk_JJ scenarios_NNS ._. Table_NNP 2_CD shows_VBZ
          univariate_NN analyses_NNS of_IN the_DT median_JJ degree_NN of_IN
          overestimation_NN for_IN scenarios_NNS with_IN and_CC without_IN specific_JJ
          patient_NN characteristics_NNS ._. Physicians_NNPS were_VBD more_RBR likely_JJ to_TO
          overestimate_NN risk_NN for_IN patients_NNS with_IN very_RB high_JJ cholesterol_NN
          levels_NNS (_( total_JJ cholesterol_NN >_NN 260_CD mg_NN /_NN dl_NN )_) than_IN for_IN
          patients_NNS with_IN more_RBR modest_JJ elevations_NNS ._. Scenarios_NNS in_IN which_WDT
          the_DT patient_NN had_VBD other_JJ CHD_NNP risk_NN factors_NNS produced_VBD smaller_JJR
          over-estimations_JJ than_IN when_WRB those_DT factors_NNS were_VBD absent_JJ ._.
          Multivariate_NNP linear_JJ regression_NN analysis_NN revealed_VBD similar_JJ
          patterns_NNS of_IN results_NNS ._. (_( data_NNS not_RB shown_VBN )_)
        
      
      
        Discussion_NNP
        In_IN this_DT scenario-based_JJ study_NN ,_, academic_JJ physicians_NNS
        overestimated_JJ the_DT risk_NN of_IN CHD_NNP events_NNS across_IN a_DT range_NN of_IN
        patient_NN risk_NN profiles_NNS encountered_VBD in_IN primary_JJ prevention_NN ._.
        Scenarios_NNS with_IN young_JJ patients_NNS ,_, female_JJ patients_NNS ,_, and_CC very_RB
        high_JJ lipid_NN levels_NNS led_VBN to_TO the_DT highest_JJS degrees_NNS of_IN
        overestimation_NN ._. Their_PRP$ estimates_NNS of_IN the_DT relative_JJ risk_NN
        reduction_NN associated_VBN with_IN therapy_NN using_VBG lipid-lowering_JJ
        drugs_NNS were_VBD more_RBR accurate_JJ ,_, but_CC their_PRP$ estimates_NNS of_IN the_DT
        absolute_JJ risk_NN reductions_NNS were_VBD also_RB inaccurate_JJ because_IN of_IN
        their_PRP$ overestimation_NN of_IN baseline_NN CHD_NNP risk_NN ._. Perhaps_RB because_IN
        of_IN the_DT over-estimation_JJ of_IN risk_NN and_CC the_DT potential_JJ benefits_NNS
        of_IN treatment_NN ,_, most_JJS physicians_NNS recommended_VBD treatment_NN in_IN most_JJS
        scenarios_NNS ,_, even_RB those_DT with_IN relatively_RB low_JJ risk_NN ._.
        Our_PRP$ study_NN provides_VBZ additional_JJ insight_NN into_IN the_DT ways_NNS in_IN
        which_WDT providers_NNS misestimate_NN risk_NN ._. It_PRP appears_VBZ that_IN providers_NNS
        are_VBP more_RBR likely_JJ to_TO overestimate_NN risk_NN in_IN young_JJ adults_NNS and_CC
        women_NNS ,_, after_IN adjusting_VBG for_IN other_JJ risk_NN factors_NNS ,_, and_CC are_VBP less_RBR
        likely_JJ to_TO make_VB such_JJ overestimations_NNS when_WRB other_JJ risk_NN factors_NNS
        are_VBP present_JJ ._. These_DT findings_NNS suggest_VBP that_IN providers_NNS '_POS
        heuristics_NNS may_MD be_VB systematically_RB inaccurate_JJ ._. Whether_IN
        feedback_NN of_IN these_DT particular_JJ errors_NNS could_MD improve_VB risk_NN
        estimation_NN has_VBZ not_RB been_VBN examined_VBN ._.
        Although_IN we_PRP did_VBD not_RB study_VB actual_JJ provider_NN behavior_NN ,_, our_PRP$
        study_NN suggests_VBZ that_IN efforts_NNS to_TO improve_VB the_DT low_JJ utilization_NN
        of_IN statin_NN drugs_NNS in_IN high-risk_JJ patients_NNS cannot_NN rely_VB solely_RB on_IN
        educational_JJ efforts_NNS aimed_VBN at_IN increasing_VBG the_DT awareness_NN of_IN
        risk_NN or_CC the_DT benefit_NN of_IN treatment_NN ._. Knowledge_NNP of_IN risk_NN ,_, or_CC the_DT
        advantages_NNS of_IN treatment_NN ,_, do_VBP not_RB appear_VB to_TO be_VB important_JJ
        barriers_NNS in_IN the_DT decision_NN to_TO prescribe_VB lipid_NN lowering_VBG agents_NNS
        among_IN physicians_NNS at_IN academic_JJ medical_JJ centers_NNS ._.
        Our_PRP$ findings_NNS are_VBP consistent_JJ with_IN previous_JJ research_NN that_WDT
        has_VBZ examined_VBN physicians_NNS '_POS ability_NN to_TO predict_VB the_DT risk_NN of_IN CHD_NNP
        events_NNS and_CC found_VBD that_IN physicians_NNS misestimate_NN absolute_JJ risk_NN ._.
        Friedmann_NNP et_CC al_NN used_VBD a_DT mail_NN survey_NN to_TO measure_VB 599_CD
        physicians_NNS '_POS estimates_NNS of_IN risk_NN for_IN three_CD CHD_NNP risk_NN scenarios_NNS ,_,
        one_CD of_IN which_WDT involved_VBD lipid-lowering_JJ therapy_NN ._. [_NN 9_CD ]_NN They_PRP
        found_VBD that_IN cardiologists_NNS were_VBD more_RBR accurate_JJ in_IN their_PRP$
        perceptions_NNS of_IN the_DT underlying_VBG risk_NN of_IN CHD_NNP than_IN general_JJ
        internists_NNS and_CC family_NN physicians_NNS ,_, but_CC that_IN estimates_NNS of_IN
        relative_JJ risk_NN reduction_NN were_VBD generally_RB accurate_JJ for_IN all_DT
        specialties_NNS ._. Cardiologists_NNP recommended_VBD treatment_NN more_RBR often_RB
        than_IN generalists_NNS ,_, even_RB though_IN they_PRP perceived_VBD the_DT benefit_NN to_TO
        be_VB smaller_JJR ._.
        Grover_NNP surveyed_VBD 253_CD Canadian_JJ physicians_NNS about_IN their_PRP$
        estimates_NNS of_IN 8_CD -_: year_NN risk_NN of_IN CHD_NNP in_IN two_CD hypothetical_JJ
        scenarios_NNS ,_, one_CD involving_VBG a_DT 40_CD year_NN old_JJ male_NN ,_, and_CC the_DT second_JJ
        involving_VBG a_DT 70_CD year-old_JJ female_JJ patient_NN ._. [_NN 8_CD ]_NN The_DT mean_NN
        estimates_NNS of_IN risk_NN were_VBD higher_JJR than_IN actual_JJ risk_NN in_IN both_DT
        scenarios_NNS ,_, but_CC the_DT degree_NN of_IN overestimation_NN was_VBD larger_JJR for_IN
        the_DT 40_CD year-old_JJ male_JJ patient_NN ._. They_PRP also_RB overestimated_JJ the_DT
        potential_JJ years_NNS of_IN life_NN saved_VBN for_IN a_DT series_NN of_IN CHD_NNP
        interventions_NNS ._.
        Chatellier_NNP et_CC al_NN provided_VBD clinical_JJ information_NN about_IN 66_CD
        patients_NNS to_TO 6_CD physicians_NNS and_CC asked_VBD the_DT physicians_NNS to_TO
        estimate_VB the_DT patients_NNS '_POS CHD_NNP risk_NN ._. Physicians_NNPS had_VBD widely_RB
        varying_VBG estimates_NNS of_IN risk_NN in_IN comparison_NN with_IN
        Framingham-derived_NNP estimates_NNS ._. The_DT agreement_NN between_IN the_DT
        Framingham_NNP estimates_NNS and_CC physicians_NNS '_POS estimates_NNS were_VBD only_RB
        moderately_RB better_JJR than_IN chance_NN for_IN 5_CD of_IN the_DT 6_CD physicians_NNS ._. [_NN
        10_CD ]_NN
        McManus_NNP examined_VBD the_DT ability_NN of_IN practice_NN nurses_NNS and_CC
        general_JJ practitioners_NNS in_IN central_JJ England_NNP to_TO estimate_VB risk_NN
        using_VBG actual_JJ patients_NNS identified_VBN from_IN computerized_JJ records_NNS ._.
        Providers_NNP '_POS subjective_JJ assessments_NNS and_CC risk_NN calculations_NNS
        from_IN 4_CD risk_NN assessment_NN tools_NNS were_VBD compared_VBN against_IN
        Framingham_NNP estimates_NNS ._. The_DT subjective_JJ assessments_NNS were_VBD less_RBR
        accurate_JJ than_IN those_DT estimates_NNS generated_VBN from_IN properly_RB
        completed_VBN risk_NN tool_NN calculations_NNS ,_, with_IN relatively_RB equal_JJ
        number_NN of_IN overestimation_NN and_CC underestimation_NN ._. [_NN 11_CD ]_NN
        Montgomery_NNP and_CC colleagues_NNS evaluated_VBD the_DT cardiovascular_JJ
        risk_NN prediction_NN ability_NN of_IN 69_CD general_JJ practitioners_NNS and_CC 11_CD
        practice_NN nurses_NNS in_IN the_DT United_NNP Kingdom_NNP ._. Providers_NNP were_VBD asked_VBN
        to_TO estimate_VB the_DT risk_NN of_IN cardiovascular_JJ events_NNS for_IN a_DT series_NN
        of_IN older_JJR patients_NNS (_( ages_NNS 60_CD -_: 79_CD )_) with_IN hypertension_NN who_WP were_VBD
        being_VBG seen_VBN in_IN the_DT practice_NN for_IN a_DT blood_NN pressure_NN check_NN ._. [_NN 12_CD
        ]_NN Estimates_NNS were_VBD compared_VBN to_TO the_DT Framingham-calculated_NNP
        risk_NN ._. Estimates_NNS were_VBD accurate_JJ in_IN 21_CD %_NN of_IN cases_NNS ;_: 63_CD %_NN were_VBD
        underestimates_NNS and_CC 16_CD %_NN overestimates_NNS ._. The_DT large_JJ number_NN of_IN
        underestimates_NNS stands_VBZ in_IN contrast_NN to_TO our_PRP$ study_NN ,_, and_CC others_NNS
        [_NN 8_CD 9_CD ]_NN that_IN mainly_RB identified_VBN overestimation_NN errors_NNS ._. This_DT
        difference_NN may_MD result_VB from_IN the_DT generally_RB high_JJ risk_NN of_IN the_DT
        patients_NNS included_VBN in_IN the_DT study_NN by_IN Montgomery_NNP and_CC colleagues_NNS
        (_( 60_CD %_NN had_VBD a_DT 5_CD year_NN risk_NN greater_JJR than_IN 15_CD %_NN )_) ._. It_PRP is_VBZ less_RBR
        likely_JJ ,_, although_IN plausible_JJ ,_, that_IN the_DT use_NN of_IN real_JJ patients_NNS
        may_MD produce_VB systematically_RB different_JJ results_NNS than_IN the_DT use_NN
        of_IN hypothetical_JJ vignettes_NNS ._.
        Our_PRP$ study_NN ,_, like_IN several_JJ previous_JJ studies_NNS in_IN this_DT area_NN ,_,
        is_VBZ limited_VBN by_IN the_DT use_NN of_IN hypothetical_JJ scenarios_NNS completed_VBN
        outside_IN of_IN usual_JJ practice_NN ._. Actual_JJ patterns_NNS of_IN risk_NN
        estimation_NN and_CC treatment_NN recommendation_NN may_MD differ_VB from_IN
        these_DT examples_NNS ._. However_RB ,_, studies_NNS suggest_VBP that_IN vignettes_NNS
        provide_VBP accurate_JJ information_NN about_IN actual_JJ physician_NN
        practice_NN ._. [_NN 14_CD 15_CD ]_NN Our_PRP$ use_NN of_IN a_DT convenience_NN sample_NN of_IN
        physicians_NNS limits_VBZ the_DT generalizability_NN of_IN our_PRP$ results_NNS ._. To_TO
        limit_VB the_DT effect_NN of_IN our_PRP$ sampling_VBG strategy_NN on_IN the_DT validity_NN
        of_IN our_PRP$ results_NNS ,_, we_PRP did_VBD not_RB inform_VB potential_JJ subjects_NNS of_IN the_DT
        specific_JJ nature_NN of_IN the_DT study_NN prior_RB to_TO their_PRP$ decision_NN to_TO
        participate_VB ._. Our_PRP$ choice_NN of_IN a_DT relative_JJ measure_NN for_IN degree_NN of_IN
        inaccuracy_NN may_MD have_VB increased_VBN the_DT apparent_JJ degree_NN of_IN
        inaccuracy_NN for_IN low-risk_JJ scenarios_NNS ._. However_RB ,_, alternate_JJ
        analysis_NN using_VBG absolute_JJ measures_NNS found_VBD similar_JJ patterns_NNS ._.
        Our_PRP$ decision_NN to_TO use_VB 5_CD year_NN risk_NN ,_, rather_RB than_IN the_DT more_RBR
        commonly_RB used_VBN 10_CD year_NN risk_NN ,_, could_MD have_VB led_VBN to_TO inaccurate_JJ
        risk_NN estimation_NN ._. We_PRP attempted_VBD to_TO limit_VB this_DT effect_NN by_IN
        reinforcing_VBG verbally_RB and_CC in_IN writing_VBG that_IN we_PRP were_VBD asking_VBG for_IN
        5_CD year_NN estimates_NNS ._. Finally_RB ,_, we_PRP did_VBD not_RB vary_VB the_DT order_NN of_IN the_DT
        scenarios_NNS ._. Subjects_NNP may_MD have_VB become_VBN fatigued_JJ or_CC may_MD have_VB
        learned_VBN from_IN answering_VBG the_DT earlier_JJR scenarios_NNS ,_, but_CC we_PRP could_MD
        detect_VB no_DT such_JJ pattern_NN ._.
      
      
        Conclusion_NNP
        Despite_IN these_DT limitations_NNS ,_, our_PRP$ findings_NNS suggest_VBP that_IN
        physicians_NNS overestimate_NN the_DT risk_NN of_IN CHD_NNP events_NNS ,_,
        particularly_RB when_WRB the_DT "_'' patient_NN "_'' has_VBZ very_RB high_JJ total_JJ or_CC LDL_NNP
        cholesterol_NN levels_NNS and_CC in_IN low-risk_JJ scenarios_NNS ,_, particularly_RB
        those_DT involving_VBG women_NNS ,_, younger_JJR patients_NNS ,_, and_CC those_DT without_IN
        other_JJ CHD_NNP risk_NN factors_NNS ._. Providers_NNP '_POS difficulties_NNS in_IN
        estimating_VBG CHD_NNP risk_NN should_MD not_RB be_VB surprising_JJ ,_, since_IN
        accurate_JJ estimation_NN requires_VBZ integration_NN of_IN several_JJ
        different_JJ pieces_NNS of_IN clinical_JJ information_NN ,_, some_DT of_IN which_WDT are_VBP
        categorical_JJ (_( smoking_NN versus_CC no_DT smoking_NN )_) and_CC others_NNS of_IN which_WDT
        are_VBP continuous_JJ (_( age_NN ,_, blood_NN pressure_NN )_) ._. Findings_NNP from_IN the_DT
        field_NN of_IN cognitive_JJ psychology_NN suggest_VBP that_IN when_WRB faced_VBN with_IN
        complex_JJ questions_NNS ,_, people_NNS ,_, including_VBG health_NN care_NN providers_NNS ,_,
        utilize_VB simpler_JJR "_'' rules-of-thumb_JJ "_'' or_CC heuristics_NNS to_TO make_VB
        decisions_NNS ._. [_NN 16_CD ]_NN In_IN some_DT cases_NNS these_DT heuristics_NNS serve_VBP
        quite_RB well_RB ;_: in_IN other_JJ cases_NNS ,_, they_PRP may_MD lead_VB to_TO common_JJ ,_,
        reproducible_JJ errors_NNS in_IN judgment_NN ._. Inaccurate_NNP estimates_NNS of_IN
        CHD_NNP risk_NN could_MD lead_VB to_TO prescription_NN of_IN lipid_NN lowering_VBG drugs_NNS
        to_TO patients_NNS in_IN whom_WP their_PRP$ net_JJ benefit_NN has_VBZ not_RB been_VBN
        established_VBN ._. [_NN 17_CD ]_NN
        Inaccurate_NNP risk_NN estimation_NN and_CC over-prescription_JJ of_IN
        risk-reducing_JJ therapies_NNS can_MD also_RB have_VB economic_JJ
        consequences_NNS ._. Cost-effectiveness_NNP analyses_NNS suggest_VBP that_IN the_DT
        cost_NN per_IN life-year_JJ saved_VBN and_CC total_JJ costs_NNS rise_VBP dramatically_RB
        as_IN treatment_NN is_VBZ extended_VBN to_TO lower-risk_JJ patients_NNS ._. [_NN 18_CD ]_NN
        Accurate_NNP risk_NN assessment_NN is_VBZ crucial_JJ for_IN making_VBG rationale_NN
        treatment_NN decisions_NNS ._. Fortunately_RB ,_, several_JJ easy_JJ to_TO use_VB and_CC
        accurate_JJ CHD_NNP risk_NN prediction_NN tools_NNS are_VBP now_RB available_JJ ._. [_NN 19_CD
        ]_NN They_PRP can_MD improve_VB the_DT accuracy_NN of_IN risk_NN predictions_NNS [_NN 11_CD ]_NN
        are_VBP becoming_VBG more_RBR widely_RB disseminated_VBN ,_, and_CC may_MD improve_VB the_DT
        quality_NN of_IN treatment_NN decisions_NNS ,_, although_IN further_JJ research_NN
        on_IN their_PRP$ effect_NN is_VBZ required_VBN ._.
      
      
        Competing_VBG interests_NNS
        After_IN the_DT completion_NN of_IN this_DT research_NN ,_, Dr_NNP ._. Michael_NNP
        Pignone_NNP has_VBZ received_VBN licensing_VBG and_CC consulting_NN fees_NNS from_IN
        Bayer_NNP ,_, Inc_NNP ._. for_IN the_DT development_NN of_IN a_DT CHD_NNP risk_NN estimation_NN
        tool_NN ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        Michael_NNP Pignone_NNP conceived_VBD of_IN the_DT idea_NN for_IN the_DT study_NN ._. He_PRP
        supervised_JJ study_NN design_NN ,_, recruited_VBD co-investigators_JJ ,_,
        oversaw_VBD pilot_NN testing_NN and_CC data_NNS collection_NN at_IN one_CD site_NN ,_, and_CC
        participated_VBD in_IN data_NNS analysis_NN ._. He_PRP drafted_VBD and_CC revised_VBD the_DT
        manuscript_NN ._. Chris_NNP Phillips_NNP participated_VBD in_IN study_NN design_NN ,_,
        conducted_VBN data_NNS analysis_NN ,_, and_CC created_VBD tables_NNS ._. He_PRP also_RB
        participated_VBD in_IN manuscript_NN editing_NN ._. Tom_NNP Elasy_NNP and_CC Alicia_NNP
        Fernandez_NNP acted_VBD as_IN site_NN supervisors_NNS for_IN data_NNS collection_NN and_CC
        revised_VBD the_DT manuscript_NN ._.
      
    
  
